RP-606 rights revert to Medivir
13-Dec-2005
"During the autumn Medivir has intensified its efforts to find an appropriate way forward for its shingles project MIV-606. With the termination of the Medivir-Reliant licensing agreement for MIV-606, all rights as well as all clinical and other data developed during the term of the agreement will be reverted to Medivir", says Medivir's CEO Lars Adlersson.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.